Posted on

Do You Have These 3 Penny Stocks Under Monitor Today?

439 Views
0 Total shares
penny stocks

Another weekend is behind us and we have a lot to look forward to going into a new week. Make sure to keep your eyes on your news scanners as Monday can be a major press release day. Obviously, in recent weeks/months, coronavirus related stocks have seen several breakouts on positive news, but do not limit yourself to one specific sector. Do you have any chart set-ups you’re currently looking at? Are specific technical indicators for a penny stock on your watch-list starting to appear bullish?

My point is this: don’t limit yourself. Don’t be afraid to cast a wide net across the market and fill your watch-list with options not always related to say, the biotech sector, a sector that has been hot-to-trot so far in 2020. As we’ve seen in recent weeks, many different penny stocks from all different sectors have gone on major breakout runs in the short-term. Could today be the day a Tweet from a company CEO turns a sub $5 penny stock into a major market contender?

Read More: Check Out These 3 Penny Stocks Currently Under $5.00

There should be a bunch of data to help provide you with important info this Monday. Already on our radar are a few contenders to put on your radar this moment. All of these are currently under $5.00 and have major news out recently. Will today be the day that one of these penny stocks scorches the market for a breakout run? Tune in and see.

Your No. 1 Monday Penny Stock To Monitor: MoSys, Inc.

MoSys, Inc. (Nasdaq: MOSY), together with its subsidiaries, operates as a semiconductor company in North America, Japan, Taiwan, and internationally. The company develops and sells integrated circuits (ICs) for the high-speed cloud networking, communications, security appliance, video, monitor and test, data center, and computing markets. It offers memory-dominated ICs under the Bandwidth Engine and Programmable HyperSpeed Engine names. The company serves cloud networking, communications, data center, and other equipment providers, as well as their subsystem and component vendors; and original equipment manufacturers through direct sales personnel, sales representatives, and distributors.

MoSys, Inc. announced that its Graph Memory Engine (GME) Accelerator IP is now running on Intel® Stratix® 10 FPGAs.

The GME is part of MoSys’ Packet Classification Platform, which was announced earlier this year, and is capable of performing embedded search and classification of packet headers. A typical use would be an alternative to TCAM functions. The proprietary platform software enables the compilation of TCAM images into graphs for GME processing. The GME product offering includes software, firmware and RTL and utilizes a common API and common RTL interface to facilitate platform portability.

Three implementations of GME will be available including:

  • Pure hardware-agnostic, software version offering maximum flexibility and capacity;
  • RTL-only version for use in an Intel FPGA for hardware-accelerated performance with no external MoSys memory device required. As it is RTL only, in addition to new designs, installed legacy systems can be reprogrammed to provide increased performance; and
  • Maximum performance version when an FPGA is connected to a MoSys® Programmable HyperSpeed Engine (PHE), with its 32 embedded 8 way threaded RISC cores.

Packet classification applications can now run much faster because the search performance on an FPGA when combined with a MoSys PHE can result in up to 100x performance improvement over a software solution running on a single core of CPU with DRAM. An implementation that utilizes the MoSys PHE provides enough additional performance to support the search throughput needed for two 100G ethernet ports.

“MoSys continues to expand the capabilities and reach of our new acceleration technology,” noted Michael Miller, MoSys’ chief technical officer. “With this new milestone of enabling our GME solution to run on Intel’s Stratix 10 FPGAs, the unique design of the MoSys platform enables software designers to leverage hardware performance without the cost or time needed to develop firmware or RTL. As importantly, our solution can be applied to a wide variety of advanced embedded applications including key-value store, networking search functions, machine learning, computation and algorithm acceleration, all of which can run on different hardware platforms.”

Your No. 2 Monday Penny Stock To Monitor: Enochian BioSciences Inc.

Enochian BioSciences Inc. (Nasdaq: ENOB) is a biopharmaceutical company dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy. Our gene-modified cell therapy platform can be applied to multiple indications, including HIV/AIDS, HBV, and Oncology.

Enochian BioSciences, Inc. announced the completion of an Initial Targeted Engagement for Regulatory Advice (INTERACT) meeting with the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT).  The meeting, which included management and scientists from Enochian BioSciences together with CBER OTAT staff, focused on the pathway forward for ENOB-HV-01. ENOB-HV-01 is a novel approach to autologous stem cell transplantation, with the potential to cure HIV by increasing engraftment of gene-modified cells that are resistant to HIV infection.  Failure to achieve engraftment has limited the success of other attempts to cure HIV with autologous transplantation.

“We considered the meeting to be very successful, with strong alignment between Enochian’s approach to developing ENOB-HV-01 and the comments of the FDA reviewers,” said Dr. Mark Dybul, Executive Vice-Chair of Enochian BioSciences. “I want to thank the reviewers from FDA CBER OTAT for their time and helpful insight during our meeting.  We look forward to advancing our thoughtful and deliberate pre-clinical work during the remainder of this year and into early next, leading to a pre-IND submission in 2021.”

Dr. W. David Hardy, Chair of Enochian BioSciences’ Scientific Advisory Board and the former Chief Medical Officer of Calimmune, said: “The novel approach we are pursuing has the potential to overcome the challenges of engraftment commonly encountered by others in the field.  While still early, thus far the data have exceeded my expectations, and I believe the FDA reviewer feedback was very much aligned with our development plan.  After more than 30 years as an HIV clinician and researcher, it is a great privilege to be involved with an enterprise with the potential to cure HIV, offering hope to millions of people.”

INTERACT is the first available FDA interaction and is a key step in the process towards a potential Investigational New Drug (IND) to study First-in-Human products potentially leading to marketing authorization via Biologics License Application (BLA).  The FDA’s Center for Biologics Evaluation and Research (CBER) has numerous INTERACT requests and only grants meetings that are deemed appropriate for this early FDA engagement.

Your No. 3 Monday Penny Stock To Monitor: Digital Ally, Inc.

Digital Ally Inc. (Nasdaq: DGLY) headquartered in Lenexa, KS, specializes in the design and manufacturing of the highest quality video recording equipment and video analytic software. Digital Ally pushes the boundaries of technology in industries such as law enforcement, emergency management, fleet safety and security. Digital Ally’s complete product solutions include vehicle and body cameras, flexible software storage, and automatic recording technology. These products work seamlessly together and are simple to install and operate. Digital Ally products are sold by domestic direct sales representatives and international distributors worldwide.

Digital Ally, Inc. recently announced the launch of two product lines in direct response to the increased safety precautions organizations and individuals are taking due to the Covid-19 pandemic.

ThermoVu™ is a non-contact temperature-measuring instrument that measures temperature through the wrist and controls entry to facilities when temperature measurements exceed pre-determined parameters. ThermoVu™ has optional features such as facial recognition to improve facility security by restricting access based on temperature and/or facial recognition reasons. ThermoVu™ provides an instant pass/fail audible tone with its temperature display and controls access to facilities based on such results. It can be widely applied in schools, office buildings, subway stations, airports and other public venues.

“We applied our years of experience with the latest cutting-edge sensor technology, real-time embedded electronics and video AI analytics in vetting and choosing the ThermoVu™ technology as the most powerful combination of fast, accurate, reliable and user friendly,” said Stan Ross, CEO of Digital Ally.

Daily updates